Business
Bionano Genomics Announces Record Number of Presentations on Optical Genome Mapping and Structural Variation at the 2021 Annual Clinical Genetics Meeting of the ACMG
Sixteen talks and posters, fourteen of which are from US institutions, to be presented across all four of Bionano’s main target growth markets: prenatal,
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Sixteen talks and posters, fourteen of which are from US institutions, to be presented across all four of Bionano’s main target growth markets: prenatal, postnatal/constitutional genetics, blood cancers and solid tumor analysis\nSAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced it largest presence to date at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics (ACMG), which is being held in a virtual format from April 13-16, 2021. The meeting features a total of sixteen presentations by Saphyr customers and Bionano scientists, almost three times the number presented last year and nearly all based on work done in the United States. “ACMG this year has the greatest number of presentations featuring Bionano data to date,” commented Erik Holmlin, PhD, CEO of Bionano Genomics. “We believe this multitude of presentations shows how significant Bionano’s presence and that of optical genome mapping (OGM) has become in the medical genetics community. The progress we are seeing here from the US market, where almost all the data being presented at ACMG comes from, is particularly encouraging since the US has a higher barrier to adoption that could be addressed with data outlining the value proposition of our products and technology. We are thrilled to share this important clinical data in all four main target segments (prenatal, postnatal/constitutional genetics, blood cancers and solid tumor analysis) at the meeting.” Blood Cancers Oral and Poster Presentations: Platform Presentation, Thursday, April 15, 2021, 5:30 pm. OP340 – Optical Genome Mapping for Assessment of Genomic Aberrations in Acute Myeloid Leukemia: A Multicenter Evaluation eP085 – Efficient workflow for detection of clinically relevant abnormalities in leukemias according to NCCN guidelineseP068 – Optical Genome Mapping Detects Rare Genetic Drivers in Pediatric B-Lymphoblastic Leukemia Prenatal Oral and Poster Presentations: Product Theater (available on demand): Next-Generation Cytogenomic Characterization of Prenatal Cases by Optical Genome MappingeP501 – Generation of a Prenatal Workflow for Identification of Structural Variation by Optical Genome Mapping (OGM) eP502 – Next-Generation Cytogenomic Characterization of Prenatal Cases by Optical Genome Mapping Post-Natal Oral and P...